Skip to content

Prospective monitoring of osteoradionecrosis after postoperative radiotherapy for oral cavity cancer.

Prospective monitoring of osteoradionecrosis after postoperative radiotherapy for oral cavity cancer.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON29332
Enrollment
120
Registered
2021-09-13
Start date
2021-10-15
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral cavity cancer, Osteoradionecrosis

Interventions

None listed

Sponsors

Erasmus MC
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - Receiving postoperative external beam radiotherapy with curative intent at the Dept of Radiotherapy at Erasmus MC (including treatment after a locoregional recurrence and/or chemoradiotherapy). - Written informed consent. - Patient 18 years or older.

Exclusion criteria

Exclusion criteria: - Patients with RT of the neck region III-V only (for instance after lymph node recurrence) - Patients who are treated simultaneously for other tumors outside the oral cavity. - Patients who previously were treated with radiotherapy in the head & neck region. - Patients with a Karnofsky Performance Status <70 - Patients with limited fluency in Dutch (inadequate to comprehend the questionnaires).

Design outcomes

Primary

MeasureTime frame
The incidence of osteoradionecrosis and the development of associated complaints over time including early signs of osteoradionecrosis after postoperative radiotherapy for oral cavity cancer

Secondary

MeasureTime frame
- Changes in quality of life and oral functioning (as measured in EORTC QLQ C30, H&N 35, Eq5D, and EAT-10) - the development of trismus, graded over time according to CTCAE 5.0 and mouth opening - the development of xerostomia, graded over time according to CTCAE 5.0 and measurements in H&N35 - the development of dysphagia, graded over time according to CTCAE 5.0 and measurements in H&N 35 & EAT-10 - the development of self-reported main symptoms of ORN (as measured in MYMOP) over time.

Contacts

Public ContactMichelle Möring

Erasmus MC

m.moring@erasmusmc.nl010 704 0704

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)